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Inhibitors  of  tumor  necrosis  factor-alpha  (TNF-α)  have  been  approved  for  treating  rheumatoid  arthritis.  As  one  of 
the  biological  response  modifiers,  etanercept  has  also  been  used  in  the  treatment  of  psoriatic  arthritis  and  inflammatory 
bowel  disease.  While  etanercept  is  effective,  certain  infectious  complications,  such  as  tuberculosis,  fungus,  and 
cytomegalovirus,  have  been  reported.  We  report  the  first  Korean  case  of  adenoviral  pneumonia  in  a  55-year-old  female 
who  developed  disseminated  adenoviral  infection  following  etanercept  treatment,  which  resolved  after  anti-TNF-α 
discontinuation.
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INTRODUCTION
Etanercept  is  the  first  anticytokine  drug  approved  to  treat 
rheumatoid  arthritis  (RA).  It  is  a  recombinant-DNA-engineered 
fusion  protein  consisting  of  an  extracellular  ligand  protein 
domain  for  tumor  necrosis  factor-α  (TNF-α)  and  the  constant 
portion  of  the  human  IgG  molecule
1).  Etanercept  has 
demonstrable  clinical  benefits  in  several  inflammatory 
arthropathies,  including  RA  and  psoriatic  arthritis
2).  Despite  trials 
indicating  their  safety,  the  wider  use  of  TNF-α-blocking  drugs 
in  patients  with  RA  has  led  to  reports  of  serious  infectious 
complications.  In  one  study,  5  of  180  patients  with  rheumatic 
disease  developed  the  following  serious  infections  while  taking 
etanercept
3).  acute  cholecystitis,  septic  wrist  caused  by 
Staphylococcus  aureus,  arthroplastic  hip  infection  caused  by 
methicillin-resistant  Staphylococcus  aureus,  psoas  abscess 
caused  by  Mycobacterium  avium-intracellulare,  and  bacteremia 
following  colonoscopy.  Pneumonia  caused  by  parainfluenza 
virus  type  3  has  also  been  reported
4).  We  report  the  first  case 
of  severe  adenovirus  pneumonia  with  myocarditis  that 
developed  in  a  patient  during  etanercept  therapy.
CASE REPORT
A  55-year-old  woman  presented  with  fever  for  3  days.  She 
had  worked  as  a  car  saleswoman  in  Pennsylvania  and  had 
arrived  in  Seoul  the  day  before  admission.  She  had  suffered 
from  RA  for  about  20  years  and  had  been  treated  with  a 
regimen  including  prednisolone,  methotrexate,  and  etanercept 
for  2  years.  She  had  received  subcutaneous  etanercept  at 
dosages  of  25  mg  twice  a  week.  She  had  noticed  progressive 
fatigue,  malaise,  anorexia,  oral  bleeding,  and  a  weight  loss  of  10 
kg  within  the  previous  3  months.  Upon  admission,  her  body 
temperature  was  37.5℃,  blood  pressure  was  120/80  mmHg, 
pulse  rate  was  104  beats  per  minute,  and  respiratory  rate  was 
18  breaths  per  minute.  On  physical  examination,  she  appeared 
chronically  ill  with  a  pale  conjunctiva,  oral  ulcer,  and  advanced 
multiple  symmetrical  joint  deformities  of  both  hands.  Her  chest 
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Figure  1.  (A)  An  initial  chest  radiograph  shows  poorly-defined 
nodular  opacities  and  consolidation  in  both  lower  lung  zones.  (B)   
A  contrast-enhanced  abdominal  CT  scan  reveals  enlarged  lymph 
nodes  with  central  attenuation  in  the  para-aortic  area.
but  no  murmur  was  noted.  All  other  findings  were  unremarkable. 
Laboratory  findings  revealed  hemoglobin  at  7.7  g/dL,  a  platelet 
count  of  40,000/mm
3,  and  a  white  blood  cell  count  of  3,000/mm
3 
with  65%  granulocytes,  26%  lymphocytes,  and  18.3%  monocytes. 
Liver  function  tests  revealed  aspartate  aminotransferase  at  447 
IU/L,  alanine  aminotransferase  at  113  IU/L,  and  albumin  at  2.4 
g/dL.  Her  rheumatoid  factor  was  2,180  IU/mL.  Antimycoplasma 
and  anti-HIV  antibodies  were  negative.  Chest  radiography 
showed  poorly-defined  nodular  opacities  in  both  lower  lung 
zones  (Figure  1A).  A  CT  scan  of  the  abdomen  revealed 
enlarged  lymph  nodes  in  the  para-aortic  area  (Figure  1B).  On 
hospital  day  4,  she  complained  of  dyspnea,  and  her  oxygen 
saturation  dropped  below  80%  while  she  was  breathing  100% 
oxygen.  She  was  intubated  and  transferred  to  the  intensive  care 
unit.  Pulmonary  hemorrhage  was  suspected,  and  chest 
radiography  showed  diffuse  bilateral  pulmonary  consolidation  in 
both  lungs  (Figure  2A).  A  CT  scan  of  the  chest  obtained  at  the 
same  time  showed  diffuse  consolidation  that  was  strongly 
suspicious  for  pulmonary  hemorrhage  combined  with  pneumonia 
(Figure  2B).  Transthoracic  echocardiography  revealed  minimal 
pericardial  effusion  with  diffuse  hypokinesia  and  a  left  ventricular 
(LV)  ejection  fraction  of  36%.  A  bone  marrow  examination 
showed  hypocellular  marrow  with  no  maturation  arrest.  We 
performed  a  bronchoscopy  that  showed  mucosal  injection  and 
fold  thickening,  but  could  not  find  a  definite  focus  of  bleeding. 
The  blood  and  endotracheal  cultures  for  bacteria,  fungus  and 
mycobacteria  were  negative.  Intravenous  immunoglobulin  (35 
g/day)  was  given  for  sepsis,  and  solucortef  (50  mg/day)  was 
maintained  for  RA.  Treatment  with  azithromycin,  ceftriaxone  and 
amikacin  was  started,  but  because  her  condition  deteriorated, 
these  were  changed  to  meropenem  and  ciprofloxacin  on 
hospital  day  10.  Her  condition  improved,  with  chest  radiograph 
showing  complete  resolution  of  previous  lesions  by  hospital  day 
40  (Figure  3).  Follow-up  echocardiography  showed  normal  LV 
systolic  function  with  an  ejection  fraction  of  70%  without 
hypokinesia.  The  result  of  endotracheal  aspiration  for  viruses 
was  positive  for  adenovirus,  which  was  confirmed  by  PCR. 
After  discharge,  she  maintained  oral  medication  including 
prednisolone  at  10  mg  per  day,  celecoxib  at  200  mg  per  day, 
hydroxychloroquine  sulfate  at  300  mg  per  day  and  methotrexate 
at  7.5  mg  per  week  through  an  outpatient  clinic  without 
complications.  She  remained  well  without  aggravating  arthralgia. 
DISCUSSION
TNF-α  is  a  cytokine  that  plays  a  critical  role  in  the 
regulation  of  inflammatory  processes  due  to  infection
5).  Early  in 
the  infectious  process,  TNF-α  promotes  the  influx  of  cells  to 
the  injured  area  to  counter  the  inciting  agent,  while  it 
subsequently  helps  to  limit  the  extent  of  damage  by  inducing 
apoptosis  and  maintaining  granuloma  formation.  These  essential 
functions  may  be  compromised  by  inhibition  of  TNF-α via  anti- 
TNF-α  blockers,  so  that  patients  who  receive  anti-TNF-α 
blocking  therapy  are  vulnerable  to  new  or  latent  infection
6). 
The  spectrum  of  pathogens  causing  invasive  disease  in 
patients  receiving  TNF-α  blockade  therapy  ranges  from 
bacteria  to  more  opportunistic  organisms  such  as  Mycobacterium 
tuberculosis,  cryptococcus  and  aspergillus
6).  A  recent  review  of 
reports  from  1998  to  2002  revealed  that  the  incidence  of 
granulomatous  infections  was  74  per  100,000  using  etanercept
7). 
M.  tuberculosis  is  the  most  frequently  reported  infection  in 
patients  treated  with  etanercept,  with  a  rate  of  35  per  100,000. 
A
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Figure 2. (A) A chest radiograph obtained on hospital day 4 shows 
diffuse  bilateral  pulmonary  consolidation  in  both  lungs  that  is 
consistent  with  diffuse  lung  injury.  (B)  A  chest  CT  scan  also 
obtained  on  hospital  day  4  shows  diffuse  consolidation  and 
ground-glass  attenuation  in  both  lungs,  as  well  as  small  bilateral 
pleural  effusions.  Enlarged  lymph  nodes  with  central  attenuation 
are  evident  in  the  right  paratracheal  area.
Figure  3.  A  chest  radiograph  obtained  on  hospital  day  40  shows 
complete  resolution  of  the  previous  findings. 
This  is  much  lower  than  the  rate  of  144  per  100,000  in 
infliximab-treated
7).  The  median  time  to  develop  the  infection  of 
M.  tuberculosis  was  reportedly  12  weeks  in  patients  treated  with 
infliximab,  whereas  it  was  46  weeks  in  those  treated  with 
etanercept
5). 
In  clinical  trials  involving  etanercept  treatment  in  RA, 
infections  of  the  upper  respiratory  tract  were  the  most 
commonly  reported,  whereas  serious  infections  requiring 
hospitalization  were  rare  and  did  not  increase  in  frequency 
during  treatment
8).  However,  in  a  more  recent  study,  serious 
and  non-serious  respiratory  tract  infections  were  significantly 
more  common  in  patients  receiving  etanercept  than  in  patients 
treated  with  conventional  disease-modifying  antirheumatic  drugs 
(7.04  versus  1.75  per  100  patient-years)
9). 
As  for  viral  infections,  TNF  is  integral  to  the  immune 
response  to  many  pathogens,  including  respiratory  viruses. 
Binding  of  TNF  cytokines  to  their  receptors  initiates  several 
signaling  pathways  culminating  in  the  activation  of  transcription 
factors,  cysteine  proteases,  which  results  in  apoptosis,  and 
cytosolic  phospholipase  A2,  an  enzyme  responsible  for  the 
production  of  inflammatory  mediators,  which  are  involved  in 
cytolysis  by  TNF
10).  Etanercept  may  allow  benign  respiratory 
viral  infections  to  progress  through  inhibition  of  TNF.
Adenoviruses  are  non-enveloped,  icosahedral  DNA  viruses 
that  cause  a  variety  of  clinical  syndromes.  The  majority  of  these 
infections  are  self-limited,  with  disseminated  disease  occurring 
rarely  in  immunocompetent  patients
11).  Most  severe  or  disseminated 
diseases  tend  to  occur  exclusively  in  immunocompromised 
patients.  Involvement  of  the  lung,  liver,  pancreas,  heart,  colon 
and  central  nervous  system  has  been  reported.  Possible  risk 
factors  in  these  disseminated  cases  include  the  underlying 
A
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medical  condition,  prolonged  hospitalization,  invasive  procedures, 
broad-spectrum  antibiotics  and  immunosuppressive  drugs
11). 
Adenovirus  is  thought  to  cause  approximately  10%  of  cases  of 
respiratory  disease  in  children.  Four  (1.3%)  of  317  Korean  adult 
patients  with  community-  acquired  pneumonia  were  diagnosed 
with  adenoviral  pneumonia  by  indirect  immunofluorescence 
staining  or  culture
12).  Adenoviruses  can  also  infect  the  mucosal 
endothelium,  as  well  as  the  epithelium
11),  which  can  lead  to 
life-threatening  hemorrhage,  as  was  observed  in  this  case. 
Furthermore,  sudden  decreased  myocardial  function  without 
identifiable  precipitating  factors  also  developed  during 
hospitalization,  and  function  fully  recovered  without  sequelae. 
This  can  be  attributed  to  adenoviral  myocarditis.  Since  TNF-α 
exerts  widespread  biological  effects  on  immune  cells,  it  is  not 
surprising  that  TNF  inhibition  results  in  a  decreased  ability  to 
control  infection  in  both  animal  models  and  humans.  In  this 
case,  adenoviral  pneumonia  with  myocarditis  was  recovered 
after  stopping  etanercept  treatment.
We  conclude  that  all  patients  should  be  thoroughly  assessed 
for  the  presence  of  any  possible  risk  factors  for  infection  prior  to 
commencement  of  etanercept  therapy.  We  recommend  close 
monitoring  for  any  infections  during  the  etanercept  treatment 
and  suggest  that  discontinuation  of  therapy  may  be  indicated 
during  the  development  of  infection
7).  Further  study  of  the 
relationship  between  etanercept  therapy  and  respiratory  viral 
infections  may  be  warranted. 
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